Pfizer, Eon Settle Neurontin Patent Claims

Law360, New York (May 3, 2011, 2:59 PM EDT) -- Pfizer Inc. agreed Thursday to drop Eon Labs Inc. from a long-running patent infringement suit in New Jersey over a generic version of the epilepsy drug Neurontin.

The terms of the settlement are confidential, but the companies stipulated that Eon's gabapentin capsules infringed Pfizer's patent and that all claims and counterclaims pending between the companies should be dismissed.

Pfizer first launched its patent suit against Eon, which later merged with Sandoz Inc., in 2001, after Eon filed an abbreviated new drug application to sell its own...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.